(3) Vision readiness classification data will be entered on the DA Form 7425 (Readiness and Deployment Checklist) IAW DA Pam 600-8-101 and entered into the Medical Protection System (MEDPROS). h. Glucose 6-Phosphate Dehydrogenase (G6-PD) Deficiency Screening: (1) IAW OTSG Memorandum dated 18 FEB 04, SUBJECT: Army Glucose 6-Phosphate (G6-PD) Deficiency Screening Program, all Army personnel (Soldiers, civilians, and other beneficiaries) will be screened for G6-PD Deficiency before receiving a prescription for, or being issued, primaquine phosphate for malaria prophylaxis. Army personnel deploying to a malarious area will have G6-PD Deficiency screening performed during pre-deployment in conjunction with routine unit or individual “Soldier Medical Readiness (SRP). G6-PD screening results have no expiration date. Therefore, only one test is required to determine if a deficiency exists. (2) Results from any quantitative G6-PD laboratory assay approved for use by the US Food and Drug Administration may be used to satisfy the screening requirement. Laboratory results of G6PD screening for Soldiers and civilian employees will be entered into the individual health record, on DD Form 2766 (Adult Preventive and Chronic Care Flowsheet), and data entered into the Medical Protection System (MEDPROS). Data entries required for G6-PD screening include date of screening, and result: D indicating deficiency of the G6-PD enzyme, and N indicating normal or no deficiency. (3) All deploying personnel found to have G6-PD deficiency will be issued Alert tags (“red dog tags”) stating: “G6PD deficient: no primaquine”, IAW AR 40-66 (para.1.c.). Para 14-1 in AR 40-66 describes the Medical Warning Tag and DA Label 162 Emergency Medical Identification Symbol known as the “Star of Life” affixed to the DD Form 2766 and DA Form 8005-series or DA Form 3444-series record jackets. Alert tags must be carried at all times and used to inform health care providers any time primaquine, or similar drug may be prescribed or issued. Sulfonamides, nitrofurantoin, phenacetin, antipyretics, quinidine, thiazide diuretics and tolbutamide can also trigger hemolytic episodes in G6-PD deficient individuals. i. Women’s Readiness: (1) Female Soldiers are required to have an annual Papanicolaou Test (PAP smear) unless they meet one of the following criteria: (2) They are 30 years of age or older with no history of dysplasia in the past and they have had three consecutive normal PAP smears. These women are required to have PAP smears/cervical cytology every three years. (3) The Soldier has had a hysterectomy with removal of the cervix for reasons other than cervical dysplasia or cancer. She is permanently exempt from the PAP smear. Those with a history of supracervical hysterectomy (cervix present) do not apply for permanent exemption. (4)
Female Soldiers age 25 years or younger are required to have annual Chlamydia
testing. (5) Women age 40 and over are required to have a mammogram a minimum of every 2 years. More frequent intervals may be indicated based on patient risk factors and clinical judgment. Female Soldiers deploying to CENTCOM AOR are required to have a mammogram within one year of deployment and a PAP smear within 6 months of deployment (within 9 months for those deploying for less than one year). (6) Women’s Health Readiness Categories are as follows (See OTSG/MEDCOM Policy Memo 09-002 for guidance on timing of pre-deployment cytology screening):
Department of the Army Personnel Policy Guidance (1 Jul 09)
Page 91